|
Match
|
Document |
Document Title |
|
|
6627224 |
Low dose entecavir formulation and use
Compositions containing a low dose of entecavir are administered on a daily basis to treat hepatitis B virus infection and/or co-infections. Formulations for the oral administration of a low dose...
|
|
|
6624210 |
Coating and excipient agent for oral or dermal dosage forms
The invention relates to a method for the production of a coating and excipient agent for oral or dermal dosage forms, consisting of (a) 35-98% by weight of a copolymer consisting of radically...
|
|
|
6623755 |
Pharmaceutical tablets
The present invention relates to novel pharmaceutical tablets useful for administering pharmaceutical active ingredients, such as bisphosphonates. These tablets have improved surface properties...
|
|
|
6620431 |
Shellac film coatings providing release at selected pH and method
Film coatings for enteric and colonic release at selected pH are provided by selecting and/or formulating a shellac of a predetermined acid number. The method includes the selection of the acid...
|
|
|
6620426 |
Tablet coating composition
A tablet coating composition including a mixture of (a) sodium alginate and (b) a polyvinylpyrrolidone-vinyl acetate copolymer, and, optionally, (c) hydroxypropylmethyl cellulose, and/or...
|
|
|
6613357 |
Osmotic device containing pseudoephedrine and an H1 antagonist
The present invention provides an osmotic device containing controlled release pseudoephedrine in the core in combination with a rapid release H1 antagonist in an external coat. A wide range of H1...
|
|
|
6613346 |
Chewable product including active ingredient
Products and methods of delivering medicaments are provided. The product includes a chewing gum center including a compressible powder that is compressed around the center. The powder includes a...
|
|
|
6610323 |
Oral pharmaceutical pulsed release dosage form
An enteric coated pharmaceutical dosage form comprising an H + ,K + -ATPase inhibitor is disclosed. The dosage form comprises at least two portions of the H + ,K + - ATPase inhibitor to be released...
|
|
|
6610327 |
Pharmaceutical moxifloxacin preparation
The present invention relates to a pharmaceutical preparation for oral administration which comprises moxifloxacin, its salt and/or hydrate and lactose, to a process for its preparation, and to the...
|
|
|
6605303 |
Oral pharmaceutical extended release dosage form
An enteric coated pharmaceutical extended release dosage form of a H + , K + -ATPase inhibitor giving an extended plasma concentration profile of a H + , K + -ATPase inhibitor. The extended plasma...
|
|
|
6602522 |
Pharmaceutical formulation for acid-labile compounds
A pharmaceutical composition of omeprazole for oral administration is described which includes: (a) a tabletted core component containing a therapeutically effective amount of a acid-labile...
|
|
|
6599529 |
Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (NSAIDs)
An oral pharmaceutical modified release multiple-units composition for the administration of a therapeutically and/or prophylactically effective amount of a non-steroid anti-inflammatory drug...
|
|
|
6599532 |
Osmotic device containing alprazolam and an antipsychotic agent
The present invention provides an osmotic device containing controlled release alprazolam in the core optionally in combination with an anti-psychotic agent, in a rapid release external coat. A...
|
|
|
6589579 |
Enhanced food products
The invention is directed to production of particles for introduction into food using a stable microjet and a monodisperse aerosol formed when the microjet dissociates. A variety of devices and...
|
|
|
6583160 |
Nicotine therapy method and oral carrier for assuaging tobacco-addiction
A method for assuaging tobacco addiction comprises pulsing doses of nicotine into a user's bloodstream so it reaches the brain before passing through the liver. A nicotine-burst tablet is held in...
|
|
|
6576260 |
Sustained-release form of administration containing tramadol saccharinate
Disclosed herein is sustained-release formulations of tramadol comprising tramadol saccharinate coated with at least one sustained-release coating. The sustained release formulations may also...
|
|
|
6576258 |
Pharmaceutical formulation with controlled release of active substances
There is disclosed a method for stabilizing active substances that are unstable in acidic medium, unstable when stored for longer periods of time in the presence of water and at the same time...
|
|
|
6572888 |
Controlled release lipoic acid
A controlled release formulation of lipoic acid is disclosed. The lipoic acid is combined with excipient materials in such a way that those materials provide for gradual release of the lipoic acid...
|
|
|
6569463 |
Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions
The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one...
|
|
|
6569456 |
Osmotic device containing diltiazem and an ACE inhibitor or diuretic
The present invention provides an osmotic device containing controlled release diltiazem in the core in combination with a rapid release ACE inhibitor, or diuretic, in an external coat. The...
|
|
|
6565880 |
Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-&lsqb 4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl&rsqb -urea
A formulation comprising, and process for preparing, improved oral dosage forms of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin
-4-yl-ethoxy)-naphthalen-1-yl]-urea, a chemical...
|
|
|
6565883 |
Controlled release oral compositions comprising rivastigmine
Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.
|
|
|
6565882 |
Antibiotic composition with inhibitor
Antibiotic composition having four dosage forms with different release profiles providing for initial release of a beta lactam antibiotic followed by release of a beta-lactamase inhibitor, followed...
|
|
|
6558701 |
Multilayer tablet for administering a fixed combination of tramadol and diclofenac
A multilayer tablet for oral administration containing at least one Tramadol layer including Tramadol or a physiologically acceptable salt thereof; at least one diclofenac layer including...
|
|
|
6558700 |
Multiple-unit sustained release tablets
A multiple-unit sustained release tablet characterized by consisiting of a granular part and a powdery part, each granule comprising a matrix composed of a water-insoluble polymer and an active...
|
|
|
6555581 |
Levothyroxine compositions and methods
The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized...
|
|
|
6555136 |
Pharmaceutical dosage form for pulsatile delivery of methylphenidate
Novel pharmaceutical dosage forms provide for pulsatile delivery of methylphenidate, i.e., release encapsulated drug in spaced apart “pulses.” The dosage forms are comprised of first, second...
|
|
|
6555145 |
Alternate encapsulation process and products produced therefrom
A novel encapsulated product is provided and includes: at least one active ingredient; at least one compressible material; and at least one tableting material; wherein the encapsulated product is...
|
|
|
6555127 |
Multi-spike release formulation for oral drug delivery
Methylphenidate or other drugs are provided in a formulation for oral administration that releases the drug in two or more pharmacokinetic spikes, by combining different release forms in a single...
|
|
|
6551621 |
Gastroprotected omeprazole microgranules, method for obtaining same and pharmaceutical preparations
The invention concerns omeprazole microgranules each comprising an active layer containing the active principle, and an outer gastroprotecting layer containing a gastroprotecting agent,...
|
|
|
6548084 |
Controlled release compositions
A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxetine.
|
|
|
6531155 |
Granulates for cosmetic and pharmaceutical preparations
Granular materials are obtainable by pressing mixtures of at least one pulverulent, rheology-modifying, carboxyl-containing polymer as main component and at least one oil-soluble component.
|
|
|
6531152 |
Immediate release gastrointestinal drug delivery system
A gastrointestinal delivery system is provided. The system comprises a drug in combination with a swellable core material, the core being surrounded by a water-insoluble or relatively...
|
|
|
6528095 |
Anti-atherosclerotic and anti-thrombotic agent and the use thereof
A pharmaceutical agent for the prevention or treatment of any of the following conditions in mammals: atherosclerosis, thrombosis, unwanted high levels of free radicals, unwanted long fibrin clot...
|
|
|
6528089 |
Method for producing solid dosing forms
Solid dosage forms are obtained by mixing at least one polymeric binder, at least one active ingredient, and, where appropriate, conventional additives to form a plastic mixture, and shaping, using...
|
|
|
RE38009 |
Zeaxanthin formulations for human ingestion
Preparations are disclosed containing the 3R-3′R stereoisomer of zeaxanthin as a sole detectable isomer, packaged for oral ingestion by humans as a therapeutic drug or nutritional supplement....
|
|
|
6517866 |
Sertraline salts and sustained-release dosage forms of sertraline
Sustained release dosage forms of sertraline which release sertraline at a rate between 1 mgA/hr and 40 mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is...
|
|
|
6517865 |
Polymer film compositions for capsules
The present invention relates to non-animal polymer compositions suitable for film forming, particularly hard and soft capsules, comprising water soluble cellulose ethers, hydrocolloides and...
|
|
|
6514532 |
Soluble form osmotic dose delivery system
Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semi-permeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage...
|
|
|
6515010 |
Carvedilol methanesulfonate
This invention relates to carvedilol methanesulfonate, compositions containing this compound and methods of using carvedilol methanesulfonate to treat hypertension, congestive heart failure and...
|
|
|
6514492 |
Taste masking of oral quinolone liquid preparations using ion exchange resins
This invention relates to the formulation of oral liquid products of quinolones or derivatives thereof using ion exchange resins, such as methacrylic acid polymer crosslinked with divinylbenzene,...
|
|
|
6514531 |
Controlled-release dosage forms comprising zolpidem or a salt thereof
The present invention relates to controlled-release dosage forms of zolpidem or salts thereof adapted to release zolpidem over a predetermined time period, according to a biphasic profile of...
|
|
|
6509038 |
Antifungal compositions with improved bioavailability
The present invention is concerned with novel pharmaceutical compositions of itraconazole which can be administered to a mammal suffering from a fungal infection, whereby a single such dosage form...
|
|
|
6506407 |
Colon-specific drug release system
A system for releasing a drug specifically in the colon of the gastrointestinal tract, which comprises a drug (b) coated with an organic acid-soluble polymer material (a), and a saccharide (c)...
|
|
|
6500459 |
Controlled onset and sustained release dosage forms and the preparation thereof
A pharmaceutical composition for controlled onset and sustained release of an active ingredient, said composition comprising: (i) a core comprising: (a) an active ingredient; (b) a hydrophilic...
|
|
|
6500451 |
Proenergetic food supplement based on NADH, octocosanol and vitamin E
The object of this invention is a food supplement based on NADH, Octocosanol and Vitamin E, which stimulates the generation of energy by the organism.
|
|
|
6500454 |
Timed, sustained release systems for propranolol
A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles...
|
|
|
6495163 |
Moisture barrier film coating composition, method and coated form
A dry moisture barrier film coating composition for forming a moisture barrier film coating for pharmaceutical tablets and the like comprises polyvinyl alcohol, soya lecithin, and optionally a flow...
|
|
|
6482447 |
Method and composition for the treatment of benign prostate hypertrophy (BPH) and prevention of prostate cancer
Compositions comprising lycopene, Serenoa repens, Pygeum africanum, and Urtica dioica are provided. The compositions are preferably formulated with an alcohol extract of the dried, cut plant...
|
|
|
6476059 |
Use of polycyclic 2-aminothiazole systems for the treatment of obesity
The invention relates to the use of polycyclic 2-aminothiazole systems and their physiologically tolerated salts and physiologically functional derivatives for the treatment of obesity. The...
|